MAPT and Alzheimer disease: CSF levels of PlGF, ANGPT2, and sPDGFRβ were elevated from early‐stage AD, that is, CDR 0.5, and were strongly related to CSF Aβ1‐40, t‐tau, p‐tau, and cognitive decline across multiple domains: CDR, MoCA, MMSE, and ADAS.